Miragen Therapeutics said this week that it has acquired from German biopharmaceutical firm T2cure the exclusive rights to technology and intellectual property related to the in vivo use of microRNA-92 as a therapeutic target.

According to the company, miR-92 is "a key regulator of neo-angiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.